Other languages Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Real-time Estimate Cboe BZX Other stock markets 02:38:52 2024-05-17 pm EDT			5-day change	1st Jan Change
3.065 ^USD	-3.01%		-6.93%	-64.85%

May. 10	Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	MT
May. 10	Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Revance Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia	May. 09
AbbVie raises annual profit forecast on strong Skyrizi sales	Apr. 26
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	Apr. 12
Revance Therapeutics Prices $100 Million Public Offering	Mar. 04
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	Feb. 28
Revance Therapeutics, Inc. Announces Executive Changes	Feb. 28
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28
Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology	Feb. 02
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	Feb. 02
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling	Dec. 12
US Consumer group seeks stronger warnings on Botox, similar treatments	Dec. 12
Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics	Nov. 08
Top Midday Decliners	23-09-19
Revance Therapeutics Forecasts Impairment Charge of Up to $100 Million Amid Restructuring, Opul Exit; Shares Fall	23-09-19
Insider Sell: Revance Therapeutics	23-09-07
'Barbie Botox' goes viral but doctors inject caution	23-09-01
Revance Therapeutics Says US FDA Approved Daxxify for Involuntary Neck Muscle Contraction	23-08-14
Revance's Botox rival gets FDA approval for painful neck muscle condition	23-08-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Other languages

Filters